LB Pharmaceuticals insider Marc Panoff reports option repricing to IPO price
Rhea-AI Filing Summary
Marc Panoff, Senior Vice President, Finance of LB Pharmaceuticals, Inc. (LBRX), reported changes to his option holdings on September 10, 2025. The filing shows a one-time option repricing that reduced the exercise price of multiple employee stock options to $15, which the company notes is the issuer's initial public offering price. The report lists several option awards affected: 3,944; 896; 1,255; 14,343; 7,171; and 90,525 shares, with some portions immediately exercisable and others subject to standard vesting schedules. Vesting details are provided for each award and the form is signed by Mr. Panoff on September 12, 2025.
Positive
- Option repricing to $15 (the IPO price) is explicitly documented, clarifying the new exercise price for affected awards
- Vesting schedules for each award are clearly stated, with some tranches immediately exercisable
- Detailed quantities of repriced options are provided (e.g., 90,525; 14,343; 7,171; 3,944; 1,255; 896)
Negative
- None.
Insights
TL;DR: Insider option repricing to the IPO price changed economics of senior executive equity awards without showing cash proceeds or share sales.
The Form 4 discloses a company-wide one-time option repricing effective 09/10/2025 that reduced multiple option exercise prices to $15, the stated IPO price. Reported derivative transactions show prior higher-priced option positions removed (disposed) and equal-sized options reissued at $15, across awards exercisable on various schedules. Aggregate notable quantities include awards of 90,525 and 14,343 shares among others. Vesting schedules remain in place as described and some tranches were immediately exercisable. The filing documents a governance action affecting executive compensation but provides no cash exercise, share sale, or dilution figures.
TL;DR: The company executed a formal option repricing to align grant exercise prices with the IPO price; vesting terms largely unchanged.
The disclosure confirms an authorized Option Repricing effective 09/10/2025 that set the per-share exercise price of repriced options to $15. The explanatory footnotes clarify that, except for the reduced exercise price, all other terms including vesting remain in full force. The report identifies the reporting person as an officer and shows signatures consistent with required filings. The filing does not include board resolutions, aggregate outstanding share counts, or explicit statements on shareholder approval, so governance context is limited to the repricing mechanics shown.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Employee Stock Option (Right to Buy) | 3,944 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 3,944 | $0.00 | -- |
| Disposition | Employee Stock Option (Right to Buy) | 896 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 896 | $0.00 | -- |
| Disposition | Employee Stock Option (Right to Buy) | 1,255 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 1,255 | $0.00 | -- |
| Disposition | Employee Stock Option (Right to Buy) | 14,343 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 14,343 | $0.00 | -- |
| Disposition | Employee Stock Option (Right to Buy) | 7,171 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 7,171 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 90,525 | $0.00 | -- |
Footnotes (1)
- Immediately exercisable. The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
